Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Healthcare Conference ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.